12 Mid Cap Stocks Just Made New 52-Week Highs
A small group of mid-cap stocks is showing notable strength, but a look inside the numbers reveals very different stories.
Strength in the mid-cap space is concentrated today, with Health Care Services, Pharmaceuticals, and Automotive Retail each placing 2 names on the 52-week-high list. In total, 12 Mid Cap stocks are at their strongest price of the past year.
The largest company on the list is Illumina (ILMN), with a market value of about $30.1 billion, after a 19.4% gain over the last month while the S&P 500 returned +0.6%. This raises the central question for any high list: is the business performance keeping pace with the stock price? Below are the names making new highs.
The Biggest Names On The List
The table below shows the 10 largest of the 12 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| ILMN | $30.1 Bil | 3.1% | 3.5% | 19.4% | 92.9% |
| FCNCA | $26.4 Bil | 6.5% | 2.6% | 4.8% | 4.1% |
| RPRX | $25.8 Bil | 0.5% | 0.8% | 6.6% | 67.0% |
| DGX | $25.1 Bil | 8.6% | 8.8% | 16.0% | 30.1% |
| LH | $24.0 Bil | 3.4% | 3.2% | 12.5% | 16.7% |
| JAZZ | $15.8 Bil | 1.8% | 5.2% | 10.7% | 119.1% |
| OHI | $15.1 Bil | 0.7% | 2.2% | 9.8% | 40.4% |
| PAG | $14.2 Bil | 0.5% | 5.3% | 22.0% | 30.3% |
| AIT | $12.8 Bil | 0.8% | 3.6% | 4.0% | 30.8% |
| MUSA | $11.5 Bil | 0.8% | 4.0% | 13.1% | 43.9% |
Which names show business strength to match the stock price?
Royalty Pharma (RPRX) presents a case where the numbers support the new high. Its revenue grew 7.8% over the last twelve months, and it operates with a 67.9% operating margin. This combination of growth and profitability is what investors look for to justify a premium.
In contrast, First Citizens BancShares (FCNCA) is also at a high, but its revenue declined 1.0% over the same period. While it trades at a lower multiple of 11.7 times trailing earnings, a new high on a shrinking top line warrants a closer look.
So what is the disciplined way to read this list?
A 52-week-high list is a map of what is working in the market. Strength often persists. But a high is a price, not a verdict on the business itself. The disciplined move is to treat this list as a starting point for research, not a finish line.
The essential next step is to check whether the business fundamentals, revenue growth, margins, and earnings, justify the stock’s new level. A strong price is only meaningful if a strong business is earning it.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
One more pattern worth noticing: 6 of the 12 names are Health Care stocks. When a whole group is making new highs together, a biotech ETF like IBB is one way to own the group’s strength without betting on which single name leads it from here.
New Highs Grow Positions Faster Than Plans Do
A new high is real progress, and it is also how winners grow into outsized positions. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.